BillionToOne, Inc. Class A (BLLN)
NASDAQ:BLLN
Want to see BLLN full AI Analyst Report?
Earnings Data
Report Date
May 06, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.03Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and financial story: exceptional top-line growth (100% YoY), margin expansion (71% gross margin, GAAP profitability), robust cash balance, multiple product launches, and payer wins including UnitedHealthcare. Key near-term risks include reimbursement timing for Northstar Response (MolDX/CMS), rising operating expenses as the company scales, oncology being a small absolute base despite rapid percentage growth, and execution dependencies for health-system integrations and broader provider awareness. Overall, the company emphasized continued momentum and conservative guidance that still leaves multiple upside catalysts unmodeled.Company Guidance
Exceptional Full-Year Growth and Profitability
Full year 2025 revenue $305.1M, up 100% year-over-year; achieved GAAP operating income of $16.0M (operating profit margin 5%) and adjusted EBITDA $38.8M (13% margin); positive cash flow from operations minus capex $16M for full year.
Fourth Quarter Acceleration
Q4 2025 revenue $96.1M, up 113% year-over-year; Q4 operating income $10.3M (11% operating margin); Q4 net income $4.4M ($0.11/diluted share).
Rapid Volume and ASP Expansion
Total tests delivered in 2025 were 610,000, up 51% year-over-year; overall ASP increased 35% to $495 for the full year and sequentially rose from $501 to $561 in Q4 (+12% quarter-over-quarter; +$60/test).
Strong Gross Margin Improvement
Company expanded gross margins to 71.4% in Q4 (up 14.3 percentage points year-over-year) driven by higher ASPs and lower COGS per test; full-year gross margins improved meaningfully vs prior year.
Oncology Ramp and Product Innovation
Oncology revenue grew to $9.1M in Q4 (+736% year-over-year), achieving a $36M oncology annualized run-rate; launched Northstar PGx and Northstar Select CH and submitted Northstar Response coverage dossier to MolDX.
Prenatal Leadership and Clinical Adoption
Prenatal revenue $86.9M in Q4 (+98% year-over-year) with a $348M prenatal annualized run-rate; UNITY Fetal Antigen NIPT supported by new MFM guideline and launched expanded Red Blood Cell Antigen and first-ever Platelet Fetal Antigen NIPT.
Payer Contracts and Major In-Network Win
Signed 44 payer contracts in 2025 adding >25M lives and reaching ~250M contracted US lives; announced in‑network contract with UnitedHealthcare effective April 1, 2026 (expected to reduce friction and improve realized ASPs).
Balance Sheet Strength
Ended year with ~$496M cash and equivalents and only ~$50M term debt, providing runway to fund growth and evidence generation.
Operational Efficiency and Capacity
Reported >10% reduction in COGS per test year-over-year (company also noted ongoing AI/automation deployment); operating productivity improved materially (36 percentage point improvement in GAAP operating margin year-over-year).
Raised 2026 Guidance
Raised 2026 revenue guidance to $430M–$445M (implying 41%–46% growth vs 2025) and reiterated expectation for positive GAAP operating income for 2026.
BLLN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BLLN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 04, 2026 | $80.83 | $72.17 | -10.71% |
Dec 09, 2025 | $109.53 | $103.70 | -5.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BillionToOne, Inc. Class A (BLLN) report earnings?
BillionToOne, Inc. Class A (BLLN) is schdueled to report earning on May 06, 2026, After Close (Confirmed).
What is BillionToOne, Inc. Class A (BLLN) earnings time?
BillionToOne, Inc. Class A (BLLN) earnings time is at May 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLLN EPS forecast?
BLLN EPS forecast for the fiscal quarter 2026 (Q1) is 0.03.